Lung metastasis of low-grade malignant soft tissue sarcoma indicates that it is already in advanced stage, and the possibility of cure is relatively small, but a series of treatments can be used to prolong the survival period of patients as much as possible, including surgical treatment, chemotherapy, targeted therapy, and participation in clinical trials. 1. Surgery: Surgery is usually not the first consideration after lung metastasis of soft tissue sarcoma, but for patients with good control of primary foci, no contraindication to surgery, and single or multiple lung metastases with limited location, patients can consider lung metastasectomy, which can effectively reduce the systemic tumor load and prolong the survival period. 2. Chemotherapy: chemotherapy is the basic treatment for lung metastasis of soft tissue sarcoma, and commonly used chemotherapeutic drugs include doxorubicin, etoposide, isocyclophosphamide and so on. It is recommended to determine the chemotherapy program according to the specific pathological type and condition. 3. Targeted therapy: patients with soft tissue sarcoma lung metastasis can also choose targeted therapy according to their conditions, and commonly used targeted drugs include sunitinib, sorafenib, bevacizumab, and erlotinib. 4. Participate in clinical trials: in the case that the existing treatments cannot control the disease, the soft tissue sarcoma treatment guidelines recommend patients to participate in clinical trials, which can use some new drugs or new treatment plans that have not yet been approved on the market, which may achieve certain therapeutic effects, but there are certain risks, and it is recommended that patients should consider it carefully. Patients with soft tissue sarcoma lung metastases are advised to seek medical attention as soon as possible, consult with a medical professional and decide on the next step of treatment to prolong the patient’s survival as much as possible.